<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Major side effects of class I antiarrhythmic drugs</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Major side effects of class I antiarrhythmic drugs</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Major side effects of class I antiarrhythmic drugs</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Zimetbaum, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3237189769"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a>, <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">mexiletine</a>, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a>, and <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a> are all class I antiarrhythmic drugs  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 1</a>) used for the treatment of various atrial and ventricular arrhythmias.</p><p>This topic will review the major side effects of the various drugs. Recommendations for the clinical role of these drugs in the treatment of atrial and ventricular arrhythmias are presented separately. (See  <a class="medical medical_review" href="/d/html/936.html" rel="external">"Overview of the acute management of tachyarrhythmias"</a>.)</p><p class="headingAnchor" id="H1911652736"><span class="h1">WHEN TO MEASURE DRUG CONCENTRATIONS</span><span class="headingEndMark"> — </span>Monitored drug concentrations are useful for patient care in several situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Acutely, when increasing or decreasing the dose, if there is concern about either an inadequate therapeutic effect or possible toxic effect</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To confirm a stable dose in a medication with narrow therapeutic window and significant potential toxicities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If you suspect unpredictable metabolism and/or elimination, caused by changes in electrolytes, kidney or liver disease (depending on the major route of elimination of the drug), older age category or congestive heart failure, all of which could result in higher than predicted concentrations resulting in drug toxicity.</p><p></p><p>More detailed information regarding recommendations for measuring drug concentrations and target drug concentrations for specific medications is available in the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="headingAnchor" id="H136469525"><span class="h1">QUINIDINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a> is a class Ia antiarrhythmic agent  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 1</a>) that can be used to treat both atrial and ventricular arrhythmias. It is no longer as commonly used as some antiarrhythmic agents, primarily due to concern about side effects  (<a class="graphic graphic_table graphicRef65568" href="/d/graphic/65568.html" rel="external">table 2</a>), particularly proarrhythmia and sudden death [<a href="#rid1">1</a>]. Quinidine is rarely used today except to prevent recurrent ventricular tachycardia in Brugada syndrome and short QT syndrome [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H3521484132"><span class="h2">Cardiovascular toxicity</span><span class="headingEndMark"> — </span>There are a variety of potential cardiac toxicities related to the administration of <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>, including proarrhythmia, conduction disturbances, hypotension, and congestive heart failure.</p><p class="headingAnchor" id="H1939010205"><span class="h3">Proarrhythmia and ventricular arrhythmias</span><span class="headingEndMark"> — </span>Ventricular arrhythmias, including isolated ventricular premature beats, couplets, bigeminy, and ventricular tachycardia, can be induced by <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> [<a href="#rid4">4</a>]. As an example, "quinidine syncope," which is probably due to self-terminating torsades de pointes (a form of polymorphic ventricular tachycardia), has been reported to occur in 1.5 percent of patients per year [<a href="#rid5">5</a>]. Thus, the induction of arrhythmias appears to reflect the proarrhythmic effect of quinidine, rather than true toxicity. Furthermore, there is suggestive evidence that these arrhythmias may be fatal, leading to lower survival rates in patients treated with quinidine. (See  <a class="medical medical_review" href="/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Class IA antiarrhythmic drugs'</a>.)</p><p><a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a> syncope and torsades de pointes are frequently associated with significant QT prolongation [<a href="#rid5">5,6</a>] precipitated or aggravated by hypokalemia, hypomagnesemia, and bradycardia, and concurrent therapy with digitalis [<a href="#rid5">5-7</a>]. Other antiarrhythmic drugs that prolong the QT interval (such as <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, and <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>) should be avoided.</p><p>Electrophysiologically-guided class 1A antiarrhythmic drug treatment with <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> appears to have a place for patients with Brugada syndrome. The results of small, nonrandomized studies in patients with Brugada syndrome with various clinical presentations and who had inducible VF have shown an excellent protective effect of quinidine during electrophysiological testing and an excellent clinical outcome in drug-treated patients. [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/106760.html" rel="external">"Brugada syndrome or pattern: Management and approach to screening of relatives"</a>.)</p><p class="headingAnchor" id="H3778188374"><span class="h4">Treatment of torsades de pointes</span><span class="headingEndMark"> — </span>Treatment of torsades de pointes requires immediate discontinuation of <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> and any other drug that prolongs the QT interval [<a href="#rid9">9</a>]. Torsades de pointes appears to be induced by triggered activity resulting from early afterdepolarizations associated with QT prolongation [<a href="#rid10">10,11</a>]. The approach to the treatment of torsades de pointes is presented separately. (See  <a class="medical medical_review" href="/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H708302562"><span class="h4">Prevention</span><span class="headingEndMark"> — </span>Alkalinization with <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> or <a class="drug drug_general" data-topicid="10267" href="/d/drug information/10267.html" rel="external">sodium lactate</a> (lactate is rapidly metabolized to bicarbonate) may diminish the proarrhythmic effect of <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> [<a href="#rid1">1,12</a>]. At the level of the sodium channel, which is blocked by quinidine in part via a charge effect of this cationic drug, alkalosis will enhance recovery of the sodium channel by at least two mechanisms [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>It will hyperpolarize the cell by decreasing the extracellular potassium concentration. (See  <a class="medical medical_review" href="/d/html/2353.html" rel="external">"Potassium balance in acid-base disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It will drive the reaction</p><p></p><p class="bulletIndent1">Qud<sup>+</sup>   +   OH<sup>–</sup>    &lt;—&gt;    QudOH</p><p></p><p class="bulletIndent1">to the right, thereby decreasing the availability of the active charged form of the drug. It has also been hypothesized that administration of a sodium containing solution directly reverses the sodium channel blockade.</p><p></p><p class="headingAnchor" id="H21524015"><span class="h4">Sex differences</span><span class="headingEndMark"> — </span>Females are more susceptible to QT interval prolongation and torsades de pointes after the administration of <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> and drugs that delay cardiac repolarization. This effect appears to be independent of serum drug concentrations. In a study of 45 healthy volunteers (21 females) which compared serum quinidine concentrations and changes in QRS and QT intervals between males and females, there were no sex differences in the plasma concentrations or pharmacokinetic variables, but demonstrated a significantly greater increase in QTc and in QRS duration when compared with men [<a href="#rid14">14,15</a>]. Thus, the disparity in prolongation of cardiac repolarization is due to a pharmacodynamic difference, and appears to involve sex-specific effects on both depolarization and repolarization.</p><p class="headingAnchor" id="H2536219478"><span class="h3">Conduction disturbances</span><span class="headingEndMark"> — </span>The cardiac toxicity associated with <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> may be initially manifested by slowed sinus or AV nodal conduction, causing sinus node conduction abnormalities or AV block [<a href="#rid16">16,17</a>]. Higher plasma concentrations may lead to marked QRS widening.</p><p class="headingAnchor" id="H57057559"><span class="h3">Hypotension</span><span class="headingEndMark"> — </span>Hypotension, requiring either slowing or cessation of intravenous therapy, occurs in approximately 25 percent of patients. Some reports have demonstrated a good response to 500 mL of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, a regimen that can be tolerated even in patients with significant HF.</p><p><a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a> can induce hypotension, particularly if large doses are administered rapidly and intravenously. The fall in blood pressure is due both to direct vasodilation and to inhibition of alpha-adrenergic mediated vasoconstriction in arteries and veins [<a href="#rid18">18</a>]. The hemodynamic effects of oral quinidine are similar but less pronounced.</p><p class="headingAnchor" id="H2232572618"><span class="h3">Increased ventricular response during atrial fibrillation or flutter</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a> can significantly increase the ventricular rate in patients with uncontrolled atrial fibrillation or flutter [<a href="#rid1">1</a>]. Two factors contribute to this response. By slowing the atrial fibrillation or atrial flutter rate, quinidine increases the likelihood that a given impulse will pass through the AV node. This tendency is enhanced by the direct vagolytic action of quinidine. Thus, conduction through the AV node must be slowed and the ventricular response controlled (using ß-blockers, calcium channel blockers, or digitalis) before therapy with quinidine is initiated in these disorders. (See  <a class="medical medical_review" href="/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p class="headingAnchor" id="H3316821643"><span class="h2">Central nervous system toxicity</span><span class="headingEndMark"> — </span>Central nervous system toxicity is associated with high-dose therapy and subsequent high plasma <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> concentrations. The constellation of symptoms that may be seen is called cinchonism and includes tinnitus, hearing loss, confusion, delirium, disturbances in vision, and psychosis. (See <a class="local">'When to measure drug concentrations'</a> above.)</p><p class="headingAnchor" id="H1809360898"><span class="h2">Gastrointestinal symptoms</span><span class="headingEndMark"> — </span>The most frequent adverse effects with oral <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> are gastrointestinal, including nausea, diarrhea, and abdominal bloating and discomfort [<a href="#rid1">1</a>]. These symptoms may be less severe with the gluconate preparation. Gastrointestinal symptoms for quinidine reportedly remain relatively high and are the most common causes for drug discontinuation [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H239999735"><span class="h2">Immune-mediated reactions</span><span class="headingEndMark"> — </span>A number of immune-mediated reactions may be induced by <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> therapy, such as rash, fever, hemolytic anemia, thrombocytopenia, leukopenia, hepatotoxicity, and anaphylaxis [<a href="#rid1">1</a>]. Thrombocytopenia, for example, results from antibodies to quinidine-platelet complexes, which cause platelets to agglutinate and lyse [<a href="#rid20">20</a>]. A lupus-like syndrome, similar to that induced by <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, is a rare problem [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p class="headingAnchor" id="H3189012877"><span class="h2">Interaction with other drugs and with grapefruit juice</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a> is metabolized by the cytochrome P450 system and it is a substrate of the CYP3A4 enzyme. Since CYP3A4 activity can be affected by grapefruit juice and a large number of other medications  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>), providers must be alert for potential quinidine toxicity when used in combination with CYP3A4 inhibitors and other cardiac drugs after grapefruit juice ingestion. (See  <a class="medical medical_review" href="/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury", section on 'Phase I reactions'</a>.)</p><p class="headingAnchor" id="H16747152"><span class="h1">DISOPYRAMIDE</span><span class="headingEndMark"> — </span>Anticholinergic symptoms are the most common side effect profile of <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>, but cardiac toxicity is of greatest concern. In particular, the negative inotropic activity and proarrhythmic potential of disopyramide limits its use in settings in which it might otherwise be effective.</p><p class="headingAnchor" id="H16747481"><span class="h2">Anticholinergic side effects</span><span class="headingEndMark"> — </span>The administration of <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> is associated with a anticholinergic symptoms including dry mouth (32 percent), urinary hesitancy (14 percent), and constipation (11 percent). As a result, disopyramide should not be used in patients with underlying conditions that may be exacerbated by decreased cholinergic activity including glaucoma, myasthenia gravis, and urinary retention.</p><p>The anticholinergic effects can be diminished by the coadministration of drugs that increase cholinergic activity such as <a class="drug drug_general" data-topicid="9770" href="/d/drug information/9770.html" rel="external">physostigmine</a>, <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a>, or <a class="drug drug_general" data-topicid="9153" href="/d/drug information/9153.html" rel="external">bethanechol</a> [<a href="#rid22">22</a>]. These agents selectively reduce anticholinergic symptoms without affecting the electrophysiologic or antiarrhythmic properties of <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> [<a href="#rid22">22,23</a>].</p><p><a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">Disopyramide</a> concentration and its metabolite, mono-N-dealkyldisopyramide, concentration should be monitored in patients whose renal function is decreased to prevent anticholinergic side effects associated with disopyramide. When serum mono-N-dealkyldisopyramide concentration is over approximately 1 microg/mL, the dose should be decreased or discontinued [<a href="#rid24">24</a>]. (See <a class="local">'When to measure drug concentrations'</a> above.)</p><p class="headingAnchor" id="H16747488"><span class="h2">Cardiac toxicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">Disopyramide</a> has substantial negative inotropic activity in humans, resulting in reductions in cardiac contractility and cardiac output, and a reflex increase in systemic vascular resistance [<a href="#rid25">25</a>]. </p><p>These changes can lead to overt heart failure (HF). HF usually occurs within the first three weeks of therapy; however, it can be seen as soon as 48 hours after initiation or several months later. This complication is most likely to occur with preexisting HF, affecting 55 percent of such patients versus only 5 percent without a prior history of heart disease. Intravenous <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> administration and concurrent renal failure are other risk factors for a significant decline in myocardial function. Patients with known significant chronic kidney disease should have serum drug concentrations measured at steady state in an effort to minimize toxicity. (See <a class="local">'When to measure drug concentrations'</a> above.)</p><p>The decline in contractility generally resolves rapidly after discontinuation of <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>. There may, however, be an acute requirement for therapy with diuretics, inotropic agents, or afterload reducing drugs. Other suggestions to enhance the safety of disopyramide in patients with underlying myocardial dysfunction include avoidance of loading doses or intravenous administration, and careful dose titration. </p><p class="headingAnchor" id="H16747495"><span class="h3">Electrocardiographic and proarrhythmic effects</span><span class="headingEndMark"> — </span>Significant widening of the QRS interval occurs in a minority of patients treated with <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>. This is most likely to occur at high circulating drug concentrations, but may be seen with values in the therapeutic range. Therapy should be discontinued until the plasma disopyramide concentration is determined.</p><p>Like other class IA antiarrhythmic drugs, <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> can prolong the QT interval, possibly leading to increased ventricular ectopy, torsades de pointes (a form of polymorphic ventricular tachycardia), or syncope [<a href="#rid26">26</a>]. Concurrent use of other class I or class III agents (such as <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> or <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>) can produce an additive increase in both the QRS and QT intervals. A similar effect can be induced by the administration of <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> or <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, drugs that inhibit the metabolism of disopyramide by inhibiting CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>) [<a href="#rid27">27-29</a>]. <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> may be safer [<a href="#rid30">30</a>], but potentially fatal ventricular arrhythmias can be induced when used in combination with disopyramide [<a href="#rid31">31</a>].</p><p><a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">Disopyramide</a> should be discontinued if the QT interval increases by more than 25 percent or ventricular ectopy is exacerbated. (See  <a class="medical medical_review" href="/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p>The proarrhythmic potential for <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> (6 percent) is less than that for the other class IA drugs, <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> (15 percent) and <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> (9 percent) [<a href="#rid32">32</a>]. With each of these drugs, the likelihood of proarrhythmia is increased by hypokalemia, hypomagnesemia, and bradyarrhythmias [<a href="#rid33">33,34</a>]. Intravenous <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> has been useful in patients with QT prolongation and torsades de pointes [<a href="#rid35">35,36</a>]. Magnesium may act by suppressing afterdepolarizations.</p><p class="headingAnchor" id="H16747502"><span class="h3">Increased ventricular response during atrial fibrillation or flutter</span><span class="headingEndMark"> — </span>Like other class IA antiarrhythmic drugs, <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> can increase the ventricular rate in patients with uncontrolled atrial fibrillation or flutter. Two factors contribute to this response: disopyramide slows the fibrillation or flutter rate, thereby making it more likely that a given impulse will pass through the AV node; and the direct anticholinergic effect of disopyramide enhances AV nodal conduction. Thus, the AV node must be slowed and the ventricular rate controlled (with ß-blockers, calcium channel blockers, or <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>) before therapy with disopyramide is begun. (See  <a class="medical medical_review" href="/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p class="headingAnchor" id="H16747524"><span class="h2">Safety of disopyramide in obstructive hypertrophic cardiomyopathy</span><span class="headingEndMark"> — </span>At the typical doses used in modern practice, <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> does not appear to induce proarrhythmia in patients with hypertrophic cardiomyopathy (HCM) with symptomatic left ventricular outflow tract obstruction. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction", section on 'Disopyramide'</a>.)</p><p>The question of outpatient safety for those requiring management with <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> has been raised. In a large outpatient clinic focused on HCM, 2015 patients were seen, including 168 who started on disopyramide. No cardiac events were seen within three months of disopyramide initiation. During long-term follow-up (255 patient-years; mean 447 days; interquartile range 201 to 779), two patients developed cardiac events (syncope of unknown cause in both). Thirty-eight (23 percent) developed side effects of disopyramide, and 18 (11 percent) stopped the drug because of these. Disopyramide at a dose of 300 mg prolonged the mean QTc interval by 19±23 msec; however, increasing the dose to 600 mg had no further significant effect [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H16747160"><span class="h1">PROCAINAMIDE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">Procainamide</a> is an effective antiarrhythmic drug; however, its use may be limited by a lupus-like syndrome and, an infrequent but potentially severe adverse effect of bone marrow toxicity.</p><p class="headingAnchor" id="H16748118"><span class="h2">Lupus-like syndrome</span><span class="headingEndMark"> — </span>Chronic administration of <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> is associated with a positive antinuclear antibody titer in patients, particularly in those who are slow acetylators. Symptoms similar to those seen in lupus (eg, arthritis, arthralgias, and pleuritis) develop in 15 to 20 percent of patients. The clinical manifestations typically remit when therapy is discontinued or changed to N-acetylprocainamide, the major active metabolite of procainamide [<a href="#rid38">38</a>]. The inability of N-acetylprocainamide to induce the lupus-like syndrome suggests an important pathogenetic role for the aromatic amino group on procainamide [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p class="headingAnchor" id="H16748125"><span class="h2">Blood dyscrasia</span><span class="headingEndMark"> — </span>Pancytopenia or agranulocytosis is a rare but potentially life-threatening complication that may be mediated by allergic, hypersensitivity, or immunologic mechanisms [<a href="#rid40">40,41</a>]. These complications are rare, with an estimated incidence of 0.22 percent, and usually develop within three months after the initiation of therapy [<a href="#rid40">40,41</a>]. Drug withdrawal is indicated in all cases; however, there is a variable degree of recovery of the white blood cell count.</p><p class="headingAnchor" id="H16748132"><span class="h2">Cardiac toxicity</span><span class="headingEndMark"> — </span>Although some cardiac side effects of <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> can be seen at therapeutic concentrations, a variety of more serious and potentially lethal effects are more common at toxic plasma concentrations (above 30 mg/L for procainamide plus its major metabolite N-acetylprocainamide versus a therapeutic range of 4 to 12 mg/L for procainamide alone). Since procainamide is largely metabolized by the liver and eliminated by the kidneys, changes in liver and kidney function could account for changes in the therapeutic concentration in adults. (See <a class="local">'When to measure drug concentrations'</a> above.)</p><p>Among the changes that can occur are:</p><p class="bulletIndent1"><span class="glyph">●</span>Conduction delay, manifested by progressive PR prolongation or widening of the QRS interval</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged refractoriness, leading to prolongation of the QT interval in proportion to the plasma <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> concentration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arrhythmias, such as ventricular premature contractions and ventricular tachycardia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe left ventricular function depression</p><p></p><p class="headingAnchor" id="H16748139"><span class="h3">Effects on ECG intervals</span><span class="headingEndMark"> — </span>The electrocardiogram can be used to monitor both the therapeutic and toxic effects of <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> on the heart. These effects are due to both a direct influence on electrophysiologic properties and the indirect impact of autonomic modulation (vagolytic properties).</p><p class="headingAnchor" id="H16748153"><span class="h4">PR interval</span><span class="headingEndMark"> — </span>When atrioventricular (AV) conduction is normal, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> has little effect on the PR interval, if however, there is preexisting slowing of AV conduction, then procainamide can depress conduction further, leading to higher degrees of AV block even at therapeutic drug concentrations. The risk of heart block in this setting is heightened since procainamide also reduces ventricular automaticity. </p><p class="headingAnchor" id="H16748160"><span class="h4">QRS duration</span><span class="headingEndMark"> — </span>Normal <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> concentrations widen the QRS complex due to slowing of conduction in the Purkinje system and ventricular muscle. The drug should be discontinued if the QRS duration increases by more than 35 to 50 percent to avoid serious toxicity. Toxic plasma concentrations can cause intraventricular conduction disturbances and reentry, resulting in ventricular arrhythmias.</p><p class="headingAnchor" id="H16748167"><span class="h4">QT interval</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">Procainamide</a> prolongs the QT interval, usually in proportion to the plasma procainamide concentration. Marked prolongation occurring in conjunction with hypokalemia can cause early afterdepolarizations and triggered activity leading to ventricular tachycardia.</p><p>Other medications that prolong the QT interval, such as fluoroquinolones and certain antihistamines  (<a class="graphic graphic_table graphicRef57431" href="/d/graphic/57431.html" rel="external">table 4</a>), should be avoided in patients with known prolongation of the QT interval, and patients receiving <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p class="headingAnchor" id="H16748181"><span class="h3">Increased ventricular response during atrial fibrillation or flutter</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">Procainamide</a>, like <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> and <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>, can significantly increase the ventricular rate in patients with uncontrolled atrial fibrillation or flutter. Two factors contribute to this response:</p><p class="bulletIndent1"><span class="glyph">●</span>By slowing the atrial rate of atrial fibrillation or atrial flutter, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> increases the likelihood that a given impulse will pass through the AV node, thereby potentially increasing the ventricular rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">Procainamide</a> has a direct vagolytic action on the AV node, increasing conduction through the AV node.</p><p></p><p>Therefore, when administering <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> for chemical cardioversion of atrial fibrillation, conduction through the AV node must be slowed and the ventricular response controlled (using ß-blockers, calcium channel blockers, or digitalis) before therapy with procainamide is initiated in these disorders [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p class="headingAnchor" id="H16747176"><span class="h1">LIDOCAINE (INTRAVENOUS)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">Lidocaine</a>, administered intravenously in the treatment of ventricular arrhythmias, is generally well tolerated. The major side effects primarily involve the central nervous system, the cardiovascular system, and the gastrointestinal tract.</p><p class="headingAnchor" id="H16750194"><span class="h2">Neurologic toxicity</span><span class="headingEndMark"> — </span>The most common adverse effect of intravenous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> is central nervous system (CNS) toxicity [<a href="#rid44">44-47</a>]. The symptoms are usually mild, dose-dependent, and resolve with a decrease in the infusion rate or discontinuation of the drug. These side effects may be particularly frequent in older adults or those with HF, and in patients with significant liver impairment in whom the metabolism of lidocaine is reduced.</p><p>Tremor is a useful bedside sign of toxicity. Other neurologic side effects include insomnia or drowsiness, lightheadedness, dysarthria and slurred speech, ataxia, depression, agitation, change in sensorium, a change in personality, nystagmus, hallucinations, memory impairment, and emotional lability.</p><p>High plasma concentrations of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> can also provoke seizures that are usually generalized [<a href="#rid48">48</a>]. This can also occur at lower drug concentrations if lidocaine is given to patients congeners of lidocaine, such as oral tocainide or <a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">mexiletine</a>. (See <a class="local">'When to measure drug concentrations'</a> above.)</p><p class="headingAnchor" id="H16750201"><span class="h2">Cardiovascular toxicity</span><span class="headingEndMark"> — </span>Cardiac side effects are an infrequent complication of intravenous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> therapy even among patients with significant underlying heart disease. The primary cardiovascular side effects include sinus slowing, asystole, hypotension, and shock. These are most often associated with overdosing or with rapid administration of lidocaine. Individuals who are older than 60 years and those with significant preexisting heart disease are at greatest risk [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H16747192"><span class="h1">MEXILETINE</span><span class="headingEndMark"> — </span>The side effects of <a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">mexiletine</a> are generally dose- and concentration-dependent. The most common adverse effects are related to the gastrointestinal and central nervous systems [<a href="#rid51">51,52</a>]. Common digestive complaints include nausea, vomiting, or heartburn. These symptoms are reversible and can be reduced by food or antacid administration. The most frequent central nervous system complaints are dizziness, lightheadedness, tremor, nervousness, difficulty with coordination, change in sleep habits, paresthesias, and numbness [<a href="#rid51">51,52</a>]. More serious noncardiac side effects are rare. </p><p class="headingAnchor" id="H16750517"><span class="h2">Cardiac complications</span><span class="headingEndMark"> — </span>There are two potential cardiac complications associated with <a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">mexiletine</a>: proarrhythmia; and impaired hemodynamics.</p><p class="headingAnchor" id="H16750524"><span class="h3">Proarrhythmia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">Mexiletine</a> has a proarrhythmic effect that is of greatest concern in patients with life-threatening arrhythmias such as sustained ventricular tachycardia [<a href="#rid53">53,54</a>]. Exacerbation of arrhythmia after mexiletine occurs in 10 to 15 percent of patients [<a href="#rid32">32</a>].</p><p><a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">Mexiletine</a> also has a depressant effect on sinus node function and can result in sinus bradycardia or prolonged sinus node recovery time in patients with preexisting sinus node dysfunction or following administration of high doses [<a href="#rid32">32,53</a>].</p><p class="headingAnchor" id="H16750531"><span class="h3">Hemodynamics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">Mexiletine</a> is usually well tolerated hemodynamically, lacking the potent negative inotropic effects seen with <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a>, and ß-blockers. Nevertheless, in patients with severe congestive HF, mexiletine should be used with caution because it can aggravate the HF or cause hypotension [<a href="#rid55">55-57</a>]. Cardiodepressant effects may be more evident in patients with severe left ventricular dysfunction. Furthermore, hepatic metabolism may be impaired in HF, resulting in prolongation of the elimination half-life of mexiletine to 25 hours.</p><p class="headingAnchor" id="H16750545"><span class="h2">Mexiletine-induced hypersensitivity syndrome</span><span class="headingEndMark"> — </span>Mexiletine-induced hypersensitivity syndrome occurs most frequently in Japanese males and is manifested by fever, rash, peripheral blood eosinophilia, and elevation of liver transaminase enzymes [<a href="#rid58">58,59</a>]. Although the mechanism for the immunogenicity is not clear, a role of reactive drug metabolites in initiating an immune response via hapten formation has been suggested. The involvement of viral infection has been explored suggesting a relationship between human herpes virus 6 and the development of systemic immune responses [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H16750559"><span class="h2">Inhibitor of CYP1A2</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">Mexiletine</a> is a potent CYP1A2 inhibitor and co-administration of mexiletine increases plasma concentrations of substrates for cytochrome P450 (CYP) 1A2 such as <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> [<a href="#rid61">61</a>], caffeine [<a href="#rid61">61,62</a>], and <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a> (a new antispastic agent) [<a href="#rid63">63</a>]. Mexiletine, approved for managing pain, painful neuropathies, and headache when used in conjunction with tizanidine may cause unpredictable changes in plasma concentrations and pharmacodynamic effects and should be used with care as it is with other substrates for CYP1A2 [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H16747200"><span class="h1">FLECAINIDE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">Flecainide</a> is an effective agent against both ventricular and supraventricular arrhythmias. However, its use is limited by concern about toxicity, particularly its proarrhythmic effects.</p><p class="headingAnchor" id="H16752027"><span class="h2">Cardiac toxicity</span></p><p class="headingAnchor" id="H16752035"><span class="h3">Proarrhythmia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">Flecainide</a> was one of two class IC antiarrhythmic medications included in the CAST trial, which evaluated patients with asymptomatic, non-life-threatening ventricular arrhythmias who were six days to two years after an acute myocardial infarction (MI) [<a href="#rid65">65</a>]. Flecainide had an apparent proarrhythmic effect with a significantly <strong>increased</strong> incidence of mortality plus nonfatal cardiac arrest (6.1 percent versus 2.3 percent in the placebo group).</p><p>It has been proposed that the increase in malignant arrhythmias was due to the use of <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> in the setting of ischemia and/or cardiac structural abnormalities (eg scar from the prior infarction). This hypothesis is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients in the CAST trial had prior MI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A case series of three patients without CHD who developed ventricular arrhythmias after <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> use for atrial fibrillation included one patient with a prosthetic mitral valve, one patient with hypertrophic cardiomyopathy, and one patient without known cardiac structural abnormalities [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">Flecainide</a> did not increase mortality when used for the treatment of supraventricular arrhythmias in structurally normal hearts [<a href="#rid67">67</a>].</p><p></p><p class="headingAnchor" id="H16752042"><span class="h3">Conduction abnormalities</span><span class="headingEndMark"> — </span>Due to its significant effect on sodium channels, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> prolongs depolarization and can slow conduction in the AV node, the His-Purkinje system, and below. These changes can lead to prolongation of the PR interval, increased QRS duration, and first- and second-degree heart block. In addition, profound sinus bradycardia can be induced in patients with preexisting sinus node disease [<a href="#rid68">68</a>]. In contrast, flecainide does not affect repolarization and therefore has little effect on the QT interval [<a href="#rid69">69</a>].</p><p>The cardiac safety profile of <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> was assessed in 227 outpatients with paroxysmal atrial fibrillation (PAF) [<a href="#rid70">70</a>]. Patients were treated with 200 mg daily for 24 weeks. The following results were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Mean QRS duration increase was 11.4 percent, and 19 percent of patients had ≥25 percent increase in QRS duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant left ventricular ejection fraction (LVEF) reduction occurred in 1.4 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bradycardia (13.2 percent) and ventricular extrasystoles (10.6 percent) were the most frequently identified proarrhythmic effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other adverse cardiac events included atrioventricular block (4.0 percent), supraventricular tachycardia (2.2 percent), bundle branch block (1.8 percent) and atrial fibrillation (1.3 percent).</p><p></p><p class="headingAnchor" id="H16752056"><span class="h2">Extracardiac effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">Flecainide</a> can induce a variety of noncardiac side effects, including dizziness, blurred vision or difficulty in focusing, headache, and nausea, each of which occurs in 10 to 20 percent of patients [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H16752099"><span class="h3">Renal dysfunction</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">Flecainide</a> accumulates in patients with renal failure; close monitoring of concentrations is needed. Although the absorption and volume of distribution of flecainide are unaffected by renal failure, the plasma elimination half-life is prolonged in mild to moderate renal impairment (10 to 30 h) compared with normal renal function (6 to 15 h). Moreover, the half-life increases further in patients with stage 5 chronic kidney disease (up to 40 h) [<a href="#rid72">72</a>]. Since flecainide is not removed efficiently by dialysis there is a potential for toxicity in patients undergoing dialysis. (See <a class="local">'When to measure drug concentrations'</a> above.)</p><p>Renal failure may predispose to toxicity at lower serum <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> concentrations and cause severe neurotoxicity [<a href="#rid73">73-75</a>]. While dizziness and visual disturbances, including diplopia, are not unusual, severe neurologic complications are rare. However, they include paranoid psychosis, dysarthria, visual hallucinations, generalized seizures and cerebello-myoclonic syndrome.</p><p class="headingAnchor" id="H16752106"><span class="h3">CYP2D6 inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">Flecainide</a> is a substrate of the hepatic enzyme system CYP2D6, which is inhibited by the selective serotonin-reuptake inhibitors (SSRIs), <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> and <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>. Thus, these CYP2D6 inhibitors also have the potential to cause central nervous system toxicity with flecainide  (<a class="graphic graphic_table graphicRef116164" href="/d/graphic/116164.html" rel="external">table 5</a>) [<a href="#rid76">76,77</a>].</p><p class="headingAnchor" id="H16747208"><span class="h1">PROPAFENONE</span><span class="headingEndMark"> — </span>Patients with known structural heart disease should <strong>not</strong> receive <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a>. Propafenone should be discontinued in patients who develop sustained VT.</p><p>Approximately 15 to 20 percent of patients taking <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a> will have side effects that require drug discontinuation [<a href="#rid78">78-80</a>]. The most common adverse reactions involve the gastrointestinal, central nervous, and cardiovascular systems. Most of these complications are dose-dependent, particularly central nervous system side effects such as dizziness, nausea, unusual taste, and blurred vision, which are often ameliorated if the propafenone dose is reduced [<a href="#rid78">78</a>]. Potential side effects involving the cardiovascular system are most concerning, as the cardiac side effects are the most life-threatening. The risk of cardiovascular toxicity is greater in patients with structural heart disease and in those treated for ventricular rather than supraventricular arrhythmias [<a href="#rid78">78,79</a>].</p><p>The relation between <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a> dose, concentration, clinical response, and toxicity is complex. The main metabolic route of propafenone is via the cytochrome P450 2D6 isoenzyme. This metabolic pathway, known to have genetic polymorphisms, is functionally absent in approximately 7 percent of White and African Americans. In these "slow metabolizers," the extent of first-pass hepatic metabolism is much less than in "extensive metabolizers," and increased plasma concentration may be more likely to cause side effects. Moreover, because the oxidative elimination of propafenone is saturable, small dose increases may cause a rapid and disproportionate increase in plasma concentrations, thus augmenting its potential for causing toxicity. (See <a class="local">'When to measure drug concentrations'</a> above.)</p><p class="headingAnchor" id="H16751133"><span class="h2">Cardiovascular effects</span></p><p class="headingAnchor" id="H16751140"><span class="h3">Inotropic effects</span><span class="headingEndMark"> — </span>In patients with a normal or minimally decreased LVEF (≥40 percent), oral <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a> can decrease the ejection fraction without causing symptoms of HF [<a href="#rid81">81</a>]. However, overt HF may be induced in patients with preexisting ventricular systolic dysfunction [<a href="#rid82">82</a>]. The negative inotropic effect of propafenone is associated with significant increases in pulmonary capillary wedge pressure and in systemic and pulmonary vascular resistance and a decline in cardiac output. Propafenone should therefore be <strong>avoided</strong> in patients with overt HF. However, propafenone can be administered cautiously to patients with mildly reduced LVEF who have no clinical signs or symptoms of HF, with close monitoring over one to two weeks for the development of HF symptoms following the initiation of therapy. </p><p class="headingAnchor" id="H16751147"><span class="h3">Chronotropic effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">Propafenone</a> has a variety of effects that can lead to bradycardia including its Class IC activity and its beta-blocker and calcium channel blocker properties. As a result, patients with known sinus node dysfunction, including the sinus node dysfunction, should <strong>not</strong> receive propafenone in the absence of a permanent pacemaker [<a href="#rid83">83</a>]. Alternatively, because potential variations in propafenone metabolism may exist and remain undetected in everyday practice, some authors have suggested a heart rate challenge, such as exercise testing, for patients using chronic propafenone [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H16751154"><span class="h3">Conduction disturbances</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">Propafenone</a> slows atrioventricular conduction and causes prolongation of the PR and QRS intervals. Prolongation of the PR interval ranges from 15 to 25 percent; it is a common finding and is not necessarily regarded as a sign of toxicity. However, on rare occasions propafenone has been associated with the development of atrioventricular block. Patients on propafenone who develop second or third degree AV block should have their dose of propafenone reduced or discontinued. </p><p><a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">Propafenone</a> has been associated with QRS prolongation, new left bundle branch block, and new right bundle branch block [<a href="#rid85">85,86</a>]. These conduction disturbances usually occur in patients with underlying heart disease and appear to be dose-dependent. No specific dose adjustments are required in this setting.</p><p class="headingAnchor" id="H16751161"><span class="h3">Proarrhythmia</span><span class="headingEndMark"> — </span>Like other antiarrhythmic agents, <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a> has a proarrhythmic effect that can trigger sustained ventricular tachycardia (VT) [<a href="#rid32">32</a>]. The proarrhythmic effect of propafenone may be somewhat reduced by its beta-blocking activity.</p><p>The potential for proarrhythmia is greater with the class IC agents, such as <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> or <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a>, compared with the IA or IB drugs  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 1</a>) [<a href="#rid87">87</a>]. The two most powerful predictors of proarrhythmia are previous VT and decreased LVEF. </p><p class="headingAnchor" id="H16751168"><span class="h2">CNS side effects</span><span class="headingEndMark"> — </span>A variety of adverse central nervous system (CNS) effects have been reported in association with <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a>, with dizziness being the most common along with nausea, unusual taste, and blurred vision. Ataxia caused by propafenone has also been reported [<a href="#rid88">88</a>]. </p><p>Although the side effects of the drug are usually dose-related, the precise mechanism is not fully understood. Blockade of beta-adrenergic receptors may be partly responsible, because this action can in itself cause CNS symptoms including sleep disturbance, depression, drowsiness, fatigue, lethargy, hallucination, delirium, paranoia, and amnesia. </p><p>In patients who develop CNS effects from <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a>, it is reasonable to consider lowering the dose in an effort to reduce side effects. If CNS side effects persist, propafenone should be discontinued. </p><p class="headingAnchor" id="H16751175"><span class="h2">Gastrointestinal side effects</span><span class="headingEndMark"> — </span>Gastrointestinal side effects from <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a>, usually mild in nature, are among the most commonly reported adverse effects. Up to 20 percent of patients receiving propafenone report an unusual taste , and up to 10 percent develop nausea. The frequency of side effects may be reduced when medication is taken with food. </p><p class="headingAnchor" id="H16751196"><span class="h2">Propafenone intoxication</span><span class="headingEndMark"> — </span>HF, conduction disturbances, and seizures are major clinical signs of intoxication. While adverse reactions to <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a> are relatively common, reports of death secondary to propafenone intoxication are comparatively rare [<a href="#rid89">89</a>]. </p><p><a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">Propafenone</a> intoxication is associated with ingested doses from 1800 to 9000 mg and serum concentrations as high as 12,000 ng/mL have been reported (normal therapeutic and toxic ranges for propafenone are 400 to 1100 ng/mL and 1100 to 2000 ng/mL, respectively) [<a href="#rid89">89,90</a>].</p><p>Treatment for <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a> intoxication centers on hemodynamic support and includes intravenous <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> (to reverse any toxicity due to the beta blocker effects), hypertonic <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, and inotropic agents [<a href="#rid90">90</a>]. A temporary pacemaker may be required for patients with high-degree AV block related to the overdose. Routine blood testing for propafenone concentrations should be performed in patients following resuscitation, particularly in patients undergoing treatment for arrhythmias. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Poisoning management'</a>.) </p><p class="headingAnchor" id="H16747216"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a><strong> side effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal – These are the most frequent adverse effects with oral <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>. Nausea, diarrhea, and abdominal bloating and discomfort can occur. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central nervous system toxicity – This is associated with high-dose therapy and subsequent high plasma <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> concentrations. The constellation of symptoms is called cinchonism and includes tinnitus, hearing loss, confusion, delirium, disturbances in vision, and psychosis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac toxicities – These include proarrhythmia with lengthening of the QT interval (potentially resulting in polymorphic ventricular tachycardia), slowed atrioventricular (AV) nodal conduction (potentially leading to heart block), and hypotension. (See <a class="local">'Quinidine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">Disopyramide</a><strong> side effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticholinergic symptoms – These include dry mouth, urinary hesitancy, and constipation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac effects – These include negative inotropic activity (potentially resulting in heart failure) and proarrhythmia with lengthening of the QT interval (potentially resulting in polymorphic ventricular tachycardia). (See <a class="local">'Disopyramide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">Procainamide</a><strong> side effects </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal disturbances.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central nervous system dysfunction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever, rash, and myalgias. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive antinuclear antibody titer – This is seen in almost all patients with chronic administration of <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>. This is particularly seen in slow acetylators, with symptoms similar to those in systemic lupus erythematosus (eg, arthritis, arthralgias, and pleuritis) in 15 to 20 percent of patients. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serious and potentially lethal cardiac effects – These are more common at toxic plasma concentrations (above 30 mg/L for <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> plus its major metabolite N-acetylprocainamide versus a therapeutic range of 4 to 12 mg/L for procainamide alone), including conduction delay (with PR prolongation or QRS widening), QT prolongation, ventricular tachyarrhythmias, increased AV nodal conduction, and depressed left ventricular function. (See <a class="local">'Procainamide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">Lidocaine</a><strong> side effects </strong>– When administered intravenously in the treatment of ventricular arrhythmias, lidocaine is generally well tolerated. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central nervous system – These include tremor, insomnia or drowsiness, lightheadedness, ataxia, and agitation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal – These include nausea, vomiting, and anorexia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular system – These include sinus node slowing, asystole, hypotension, and shock. (See <a class="local">'Lidocaine (intravenous)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">Mexiletine</a><strong> side effects </strong>– The side effects of mexiletine are generally dose and concentration dependent. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal tract – These are the most common adverse effects and include nausea, vomiting, or heartburn. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central nervous system – These include dizziness, lightheadedness, tremor, nervousness, difficulty with coordination, change in sleep habits, paresthesias, and numbness.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac – A proarrhythmic effect can contribute to ventricular tachyarrhythmias. (See <a class="local">'Mexiletine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">Flecainide</a><strong> side effects </strong>– This is generally well tolerated, though it can induce a variety of generally mild and tolerable side effects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noncardiac – These include dizziness, blurred vision or difficulty in focusing, headache, and nausea, each of which occurs in 10 to 20 percent of patients. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac – Proarrhythmia and the potential for fatal ventricular arrhythmias can occur in persons with structural heart disease. Conversely, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> does not appear to increase mortality when used for the treatment of supraventricular arrhythmias in persons with structurally normal hearts. (See <a class="local">'Flecainide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">Propafenone</a><strong> side effects </strong>– Approximately 15 to 20 percent of patients taking propafenone will have side effects that require drug discontinuation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal – These are the most common and include nausea and an unusual taste sensation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central nervous system – Most commonly, dizziness occurs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular – These include negative inotropic effects, bradycardia and AV block, and proarrhythmia. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Overdose – <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">Propafenone</a> intoxication, often due to overdose, is a life-threatening condition marked by heart failure, hemodynamically-unstable ventricular tachyarrhythmias and/or bradyarrhythmias, and seizures. (See <a class="local">'Propafenone'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977; 20:151.</a></li><li><a class="nounderline abstract_t">Viskin S, Chorin E, Viskin D, et al. Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. Circulation 2019; 139:2304.</a></li><li><a class="nounderline abstract_t">Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004; 43:1494.</a></li><li><a class="nounderline abstract_t">Morganroth J, Horowitz LN. Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias. Am J Cardiol 1985; 56:585.</a></li><li><a class="nounderline abstract_t">Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111:1088.</a></li><li><a class="nounderline abstract_t">Koster RW, Wellens HJ. Quinidine-induced ventricular flutter and fibrillation without digitalis therapy. Am J Cardiol 1976; 38:519.</a></li><li><a class="nounderline abstract_t">Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987; 59:32E.</a></li><li><a class="nounderline abstract_t">Belhassen B, Rahkovich M, Michowitz Y, et al. Management of Brugada Syndrome: Thirty-Three-Year Experience Using Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs. Circ Arrhythm Electrophysiol 2015; 8:1393.</a></li><li><a class="nounderline abstract_t">Minardo JD, Heger JJ, Miles WM, et al. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 1988; 319:257.</a></li><li><a class="nounderline abstract_t">Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 1985; 56:857.</a></li><li><a class="nounderline abstract_t">Levine JH, Spear JF, Guarnieri T, et al. Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation 1985; 72:1092.</a></li><li><a class="nounderline abstract_t">WASSERMAN F, BRODSKY L, KATHE JH, et al. The effect of molar sodium lactate in quinidine intoxication. Am J Cardiol 1959; 3:294.</a></li><li><a class="nounderline abstract_t">Mason JW, Hondeghem LM. Quinidine. Ann N Y Acad Sci 1984; 432:162.</a></li><li><a class="nounderline abstract_t">El-Eraky H, Thomas SH. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol 2003; 56:198.</a></li><li><a class="nounderline abstract_t">Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67:413.</a></li><li><a class="nounderline abstract_t">SHORT DS. The syndrome of alternating bradycardia and tachycardia. Br Heart J 1954; 16:208.</a></li><li><a class="nounderline abstract_t">Grayzel J, Angeles J. Sino-atrial block in man provoked by quinidine. J Electrocardiol 1972; 5:289.</a></li><li><a class="nounderline abstract_t">Motulsky HJ, Maisel AS, Snavely MD, Insel PA. Quinidine is a competitive antagonist at alpha 1- and alpha 2-adrenergic receptors. Circ Res 1984; 55:376.</a></li><li><a class="nounderline abstract_t">Li DL, Cox ZL, Richardson TD, et al. Quinidine in the Management of Recurrent Ventricular Arrhythmias: A Reappraisal. JACC Clin Electrophysiol 2021; 7:1254.</a></li><li><a class="nounderline abstract_t">SHULMAN NR. Immunoreactions involving platelets. I. A steric and kinetic model for formation of a complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complement by the complex. J Exp Med 1958; 107:665.</a></li><li><a class="nounderline abstract_t">Cohen MG, Kevat S, Prowse MV, Ahern MJ. Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med 1988; 108:369.</a></li><li><a class="nounderline abstract_t">Teichman SL, Ferrick A, Kim SG, et al. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol 1987; 10:633.</a></li><li><a class="nounderline abstract_t">Konishi T, Kadoya M, Ikeguchi S, et al. Combined effect of disopyramide and bethanechol: use of bethanechol to prevent anticholinergic side effects of disopyramide without reduction of antiarrhythmic efficacy. J Cardiovasc Pharmacol 1989; 14:341.</a></li><li><a class="nounderline abstract_t">Tsuchishita Y, Fukumoto K, Kusumoto M, Ueno K. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide. Biol Pharm Bull 2008; 31:1368.</a></li><li><a class="nounderline abstract_t">Di Bianco R, Gottdiener JS, Singh SN, Fletcher RD. A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation. Angiology 1987; 38:174.</a></li><li><a class="nounderline abstract_t">Casedevant B, Sabaut D, Clementy J, Dallocchio M. [Letter: Syncopes through the inversion of points in connection with the absorption of disopyramide]. Nouv Presse Med 1975; 4:2339.</a></li><li><a class="nounderline abstract_t">Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1999; 1:206.</a></li><li><a class="nounderline abstract_t">Hayashi Y, Ikeda U, Hashimoto T, et al. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999; 22:672.</a></li><li><a class="nounderline abstract_t">Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.</a></li><li><a class="nounderline abstract_t">Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18 Suppl 1:S71.</a></li><li><a class="nounderline abstract_t">Granowitz EV, Tabor KJ, Kirchhoffer JB. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol 2000; 23:1433.</a></li><li><a class="nounderline abstract_t">Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.</a></li><li><a class="nounderline abstract_t">Wald RW, Waxman MB, Colman JM. Torsade de pointes ventricular tachycardia. A complication of disopyramide shared with quinidine. J Electrocardiol 1981; 14:301.</a></li><li><a class="nounderline abstract_t">Schweitzer P, Mark H. Torsade de pointes caused by disopyramide and hypokalemia. Mt Sinai J Med 1982; 49:110.</a></li><li><a class="nounderline abstract_t">Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392.</a></li><li><a class="nounderline abstract_t">Tzivoni D, Keren A, Stern S, Gottlieb S. Disopyramide-induced Torsade de Pointes. Arch Intern Med 1981; 141:946.</a></li><li><a class="nounderline abstract_t">Adler A, Fourey D, Weissler-Snir A, et al. Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients. J Am Heart Assoc 2017; 6.</a></li><li><a class="nounderline abstract_t">Stec GP, Lertora JJ, Atkinson AJ Jr, et al. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. Ann Intern Med 1979; 90:799.</a></li><li><a class="nounderline abstract_t">Reidenberg MM, Drayer DE. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus. Angiology 1986; 37:968.</a></li><li><a class="nounderline abstract_t">Danielly J, DeJong R, Radke-Mitchell LC, Uprichard AC. Procainamide-associated blood dyscrasias. Am J Cardiol 1994; 74:1179.</a></li><li><a class="nounderline abstract_t">Ellrodt AG, Murata GH, Riedinger MS, et al. Severe neutropenia associated with sustained-release procainamide. Ann Intern Med 1984; 100:197.</a></li><li><a class="nounderline abstract_t">Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20:289.</a></li><li><a class="nounderline abstract_t">Perkins A, Marill K. Accelerated AV nodal conduction with use of procainamide in atrial fibrillation. J Emerg Med 2012; 42:e47.</a></li><li><a class="nounderline abstract_t">Rademaker AW, Kellen J, Tam YK, Wyse DG. Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clin Pharmacol Ther 1986; 40:71.</a></li><li><a class="nounderline abstract_t">Chopra MP, Thadani U, Portal RW, Aber CP. Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double-blind trial. Br Med J 1971; 3:668.</a></li><li><a class="nounderline abstract_t">Gianelly R, von der Groeben JO, Spivack AP, Harrison DC. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med 1967; 277:1215.</a></li><li><a class="nounderline abstract_t">Lown B, Vassaux C. Lidocaine in acute myocardial infarction. Am Heart J 1968; 76:586.</a></li><li><a class="nounderline abstract_t">DeToledo JC. Lidocaine and seizures. Ther Drug Monit 2000; 22:320.</a></li><li><a class="nounderline abstract_t">Pfeifer HJ, Greenblatt DJ, Koch-Weser J. Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J 1976; 92:168.</a></li><li><a class="nounderline abstract_t">Schumacher RR, Lieberson AD, Childress RH, Williams JF Jr. Hemodynamic effects of lidocaine in patients with heart disease. Circulation 1968; 37:965.</a></li><li><a class="nounderline abstract_t">Johansson BW, Stavenow L, Hanson A. Long-term clinical experience with mexiletine. Am Heart J 1984; 107:1099.</a></li><li><a class="nounderline abstract_t">Talbot RG, Julian DG, Prescott LF. Long-term treatment of ventricular arrhythmias with oral mexiletine. Am Heart J 1976; 91:58.</a></li><li><a class="nounderline abstract_t">Velebit V, Podrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982; 65:886.</a></li><li><a class="nounderline abstract_t">Campbell RW. Arrhythmogenesis--a European perspective. Am J Cardiol 1987; 59:49E.</a></li><li><a class="nounderline abstract_t">Sami M, Lisbona R. Mexiletine: long-term efficacy and hemodynamic actions in patients with ventricular arrhythmia. Can J Cardiol 1985; 1:251.</a></li><li><a class="nounderline abstract_t">Shanks RG. Hemodynamic effects of mexiletine. Am Heart J 1984; 107:1065.</a></li><li><a class="nounderline abstract_t">Stein J, Podrid P, Lown B. Effects of oral mexiletine on left and right ventricular function. Am J Cardiol 1984; 54:575.</a></li><li><a class="nounderline abstract_t">Sasaki K, Yamamoto T, Kishi M, et al. Acute exanthematous pustular drug eruption induced by mexiletine. Eur J Dermatol 2001; 11:469.</a></li><li><a class="nounderline abstract_t">Lee SP, Kim SH, Kim TH, et al. A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia. J Korean Med Sci 2010; 25:148.</a></li><li><a class="nounderline abstract_t">Sekiguchi A, Kashiwagi T, Ishida-Yamamoto A, et al. Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation. J Dermatol 2005; 32:278.</a></li><li><a class="nounderline abstract_t">Kendall JD, Chrymko MM, Cooper BE. Theophylline-mexiletine interaction: a case report. Pharmacotherapy 1992; 12:416.</a></li><li><a class="nounderline abstract_t">Hurwitz A, Vacek JL, Botteron GW, et al. Mexiletine effects on theophylline disposition. Clin Pharmacol Ther 1991; 50:299.</a></li><li><a class="nounderline abstract_t">Momo K, Homma M, Osaka Y, et al. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2010; 50:331.</a></li><li><a class="nounderline abstract_t">Marmura MJ, Passero FC Jr, Young WB. Mexiletine for refractory chronic daily headache: a report of nine cases. Headache 2008; 48:1506.</a></li><li><a class="nounderline abstract_t">Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.</a></li><li><a class="nounderline abstract_t">Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111:107.</a></li><li><a class="nounderline abstract_t">Pritchett EL, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991; 67:976.</a></li><li><a class="nounderline abstract_t">Vik-Mo H, Ohm OJ, Lund-Johansen P. Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction. Am J Cardiol 1982; 50:1090.</a></li><li><a class="nounderline abstract_t">Hellestrand KJ, Bexton RS, Nathan AW, et al. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 1982; 48:140.</a></li><li><a class="nounderline abstract_t">Aliot E, De Roy L, Capucci A, et al. Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angeiol (Paris) 2003; 52:34.</a></li><li><a class="nounderline abstract_t">Gentzkow GD, Sullivan JY. Extracardiac adverse effects of flecainide. Am J Cardiol 1984; 53:101B.</a></li><li><a class="nounderline abstract_t">Williams AJ, McQuinn RL, Walls J. Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther 1988; 43:449.</a></li><li><a class="nounderline abstract_t">Ting SM, Lee D, Maclean D, Sheerin NS. Paranoid psychosis and myoclonus: flecainide toxicity in renal failure. Cardiology 2008; 111:83.</a></li><li><a class="nounderline abstract_t">Ghika J, Goy JJ, Naegeli C, Regli F. Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy. Schweiz Arch Neurol Psychiatr (1985) 1994; 145:4.</a></li><li><a class="nounderline abstract_t">Bennett MI. Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Pain 1997; 70:93.</a></li><li><a class="nounderline abstract_t">Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51:73.</a></li><li><a class="nounderline abstract_t">Lim KS, Cho JY, Jang IJ, et al. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 2008; 66:660.</a></li><li><a class="nounderline abstract_t">Ravid, S, Podrid, et al. Safety of long term propafenone therapy for cardiac arrhythmia: Experience with 774 patients. J Electrophysiol 1987; 1:580.</a></li><li><a class="nounderline abstract_t">Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996; 78:430.</a></li><li><a class="nounderline abstract_t">Schlepper M. Propafenone, a review of its profile. Eur Heart J 1987; 8 Suppl A:27.</a></li><li><a class="nounderline abstract_t">Baker BJ, Dinh H, Kroskey D, et al. Effect of propafenone on left ventricular ejection fraction. Am J Cardiol 1984; 54:20D.</a></li><li><a class="nounderline abstract_t">Brodsky MA, Allen BJ, Abate D, Henry WL. Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. Am Heart J 1985; 110:794.</a></li><li><a class="nounderline abstract_t">Stohler, JL, Kowey, et al. Drug interactions with propafenone. J Electrophysiol 1987; 1:568.</a></li><li><a class="nounderline abstract_t">Dilaveris, P, Synetos, et al. Exercise-induced left bundle branch block and propafenone administration. Int J Cardiology 2006; 106:279.</a></li><li><a class="nounderline abstract_t">de Soyza N, Terry L, Murphy ML, et al. Effect of propafenone in patients with stable ventricular arrhythmias. Am Heart J 1984; 108:285.</a></li><li><a class="nounderline abstract_t">Podrid PJ, Lown B. Propafenone: a new agent for ventricular arrhythmia. J Am Coll Cardiol 1984; 4:117.</a></li><li><a class="nounderline abstract_t">Dhein S, Müller A, Gerwin R, Klaus W. Comparative study on the proarrhythmic effects of some antiarrhythmic agents. Circulation 1993; 87:617.</a></li><li><a class="nounderline abstract_t">Odeh M, Seligmann H, Oliven A. Propafenone-induced ataxia: report of three cases. Am J Med Sci 2000; 320:151.</a></li><li><a class="nounderline abstract_t">Clarot F, Goullé JP, Horst M, et al. Fatal propafenone overdoses: case reports and a review of the literature. J Anal Toxicol 2003; 27:595.</a></li><li><a class="nounderline abstract_t">Ovaska H, Ludman A, Spencer EP, et al. Propafenone poisoning--a case report with plasma propafenone concentrations. J Med Toxicol 2010; 6:37.</a></li></ol></div><div id="topicVersionRevision">Topic 86747 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/331400" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30696267" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093889" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Short QT syndrome: pharmacological treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3901720" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3716982" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/970334" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Quinidine-induced ventricular flutter and fibrillation without digitalis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3107364" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for the development of proarrhythmic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26354972" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management of Brugada Syndrome: Thirty-Three-Year Experience Using Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3393179" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4006095" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4042297" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13626863" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of molar sodium lactate in quinidine intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6395759" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Quinidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12895193" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10801251" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Greater quinidine-induced QTc interval prolongation in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13160273" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The syndrome of alternating bradycardia and tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5071356" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sino-atrial block in man provoked by quinidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6147208" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Quinidine is a competitive antagonist at alpha 1- and alpha 2-adrenergic receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217656" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Quinidine in the Management of Recurrent Ventricular Arrhythmias: A Reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13525578" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunoreactions involving platelets. I. A steric and kinetic model for formation of a complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complement by the complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3257671" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Two distinct quinidine-induced rheumatic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3624669" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2476611" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combined effect of disopyramide and bethanechol: use of bethanechol to prevent anticholinergic side effects of disopyramide without reduction of antiarrhythmic efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591776" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3103491" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1178509" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : [Letter: Syncopes through the inversion of points in connection with the absorption of disopyramide].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11720625" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Torsades de pointes due to drug interaction between disopyramide and clarithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10234723" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356306" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Oral erythromycin and the risk of sudden death from cardiac causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574199" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparative safety of the different macrolides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025903" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Potentially fatal interaction between azithromycin and disopyramide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437788" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7264507" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Torsade de pointes ventricular tachycardia. A complication of disopyramide shared with quinidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979692" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Torsade de pointes caused by disopyramide and hypokalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3338130" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of torsade de pointes with magnesium sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235820" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Disopyramide-induced Torsade de Pointes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28550094" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/312047" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2433971" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977085" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Procainamide-associated blood dyscrasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691661" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Severe neutropenia associated with sustained-release procainamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12641485" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Fluoroquinolones in the elderly: safety considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237259" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Accelerated AV nodal conduction with use of procainamide in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3522031" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Character of adverse effects of prophylactic lidocaine in the coronary care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4936439" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4862377" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5676329" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lidocaine in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10850400" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lidocaine and seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/941829" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4871180" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hemodynamic effects of lidocaine in patients with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6720535" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term clinical experience with mexiletine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/53994" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term treatment of ventricular arrhythmias with oral mexiletine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6176355" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578041" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Arrhythmogenesis--a European perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2413974" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mexiletine: long-term efficacy and hemodynamic actions in patients with ventricular arrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6372422" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hemodynamic effects of mexiletine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6475776" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of oral mexiletine on left and right ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11525960" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Acute exanthematous pustular drug eruption induced by mexiletine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20052362" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863850" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1437703" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Theophylline-mexiletine interaction: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1914365" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mexiletine effects on theophylline disposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789372" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18793209" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mexiletine for refractory chronic daily headache: a report of nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900101" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2500880" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1902055" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7137036" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7093083" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12710293" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6695813" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Extracardiac adverse effects of flecainide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3128417" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pharmacokinetics of flecainide acetate in patients with severe renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376118" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Paranoid psychosis and myoclonus: flecainide toxicity in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526455" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106813" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880055" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18754843" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety of long term propafenone therapy for cardiac arrhythmia: Experience with 774 patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752188" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3556176" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Propafenone, a review of its profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6496365" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of propafenone on left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4050651" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Drug interactions with propafenone</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Exercise-induced left bundle branch block and propafenone administration</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6380253" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effect of propafenone in patients with stable ventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6376591" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Propafenone: a new agent for ventricular arrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425305" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Comparative study on the proarrhythmic effects of some antiarrhythmic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10981493" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Propafenone-induced ataxia: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14670140" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Fatal propafenone overdoses: case reports and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20373066" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Propafenone poisoning--a case report with plasma propafenone concentrations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
